Andrew Cooper
Stock Analyst at Raymond James
(2.35)
# 2,583
Out of 4,915 analysts
143
Total ratings
42.52%
Success rate
-1.16%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $90.35 | +27.28% | 9 | Jul 29, 2025 | |
| ITGR Integer Holdings | Maintains: Outperform | $150 → $143 | $108.17 | +32.21% | 3 | Jul 25, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $481.47 | +11.12% | 7 | Jul 24, 2025 | |
| HAE Haemonetics | Reiterates: Strong Buy | $115 → $105 | $75.23 | +39.58% | 9 | May 9, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $4.02 | +149.07% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $17.33 | +44.26% | 2 | May 5, 2025 | |
| HOLX Hologic | Reiterates: Outperform | $90 → $71 | $67.29 | +5.51% | 12 | May 2, 2025 | |
| UFPT UFP Technologies | Initiates: Market Perform | n/a | $227.00 | - | 1 | Mar 28, 2025 | |
| GH Guardant Health | Reiterates: Outperform | $39 → $59 | $41.33 | +42.77% | 3 | Feb 21, 2025 | |
| AVTR Avantor | Reiterates: Outperform | $26 → $24 | $13.77 | +74.36% | 14 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $202.95 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $49.53 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.45 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $137.52 | -38.19% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $23.83 | +218.93% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $3.53 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $33.31 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.01 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $23.86 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.23 | - | 5 | Sep 22, 2021 |
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $90.35
Upside: +27.28%
Integer Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $150 → $143
Current: $108.17
Upside: +32.21%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $481.47
Upside: +11.12%
Haemonetics
May 9, 2025
Reiterates: Strong Buy
Price Target: $115 → $105
Current: $75.23
Upside: +39.58%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $4.02
Upside: +149.07%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $17.33
Upside: +44.26%
Hologic
May 2, 2025
Reiterates: Outperform
Price Target: $90 → $71
Current: $67.29
Upside: +5.51%
UFP Technologies
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $227.00
Upside: -
Guardant Health
Feb 21, 2025
Reiterates: Outperform
Price Target: $39 → $59
Current: $41.33
Upside: +42.77%
Avantor
Feb 10, 2025
Reiterates: Outperform
Price Target: $26 → $24
Current: $13.77
Upside: +74.36%
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $202.95
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $49.53
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $12.45
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $137.52
Upside: -38.19%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $23.83
Upside: +218.93%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $3.53
Upside: -
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $33.31
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.01
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $23.86
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.23
Upside: -